As a HER2 targeted drug, Tucatinib has shown significant efficacy in the treatment of breast cancer and colorectal cancer, especially in patients with brain metastases.

1. Core efficacy data

(1) Treatment of breast cancer: the median progression free survival period of the combined scheme reached 7.8 months, and the disease control rate of patients with brain metastases increased to 52%.

(2) Colorectal cancer treatment: The objective response rate is 38.1%, and the median duration of response is 8.5 months.

2. Advantages of Mechanism of Action

(1) High selectivity: Only inhibits HER2 tyrosine kinase to avoid EGFR related side effects.

(2) Blood brain barrier penetration: exhibits unique activity against HER2 positive brain metastases.

3 Clinical Benefit Characteristics

(1) Back line treatment: maintains significant anti-tumor activity in treated patients.

(2) Combined efficacy enhancement: synergistically blocks the HER2 signaling pathway with trastuzumab.

4 Factors affecting therapeutic efficacy

(1) Biomarker: HER2 positivity directly affects drug response rate.

(2) Drug resistance management: Combination therapy can delay the onset of acquired drug resistance.